Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,252 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bowel Diseases, Inflammatory Clear all
Recruiting Not applicable Interventional

Behavioral Therapy for Crohn's Disease

NCT06512597
View directory record Official record
Conditions
Crohn's Disease
Interventions
Primary Intervention for Combination Therapy - IBD Coping Strategies Program, Time and Attention Control - IBD Support Program
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jun 25, 2026, 5:28 PM EDT
Not yet recruiting Not applicable Interventional

Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE) in Participants With Inflammatory Bowel Disease (IBD)

NCT06989424
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Colonoscopy
Interventions
Magnetic Flexible Endoscope (MFE)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Not yet recruiting Phase 2 Interventional

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

NCT07513181
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Interventions
ATH-063, Placebo
Drug · Other
Lead sponsor
Athos Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Miami, Florida • Roswell, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Fecal Transplant for Ulcerative Colitis

NCT03948919
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal microbiota, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jun 25, 2026, 5:28 PM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

NCT04314375
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose Budesonide, High Dose Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

NCT03945019
View directory record Official record
Conditions
Crohn's Disease
Interventions
CT-P13 SC (Infliximab), Placebo SC
Biological · Other
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 75 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional Results available

Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova

NCT01433471
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Trichuris suis ova
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 72 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Jun 25, 2026, 5:28 PM EDT
Withdrawn Phase 2 Interventional

Immune Ablation and Stem Cell Support for Crohn's Disease

NCT00179842
View directory record Official record
Conditions
Crohn Disease
Interventions
Stem Cell Transplant
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jun 25, 2026, 5:28 PM EDT
Withdrawn Phase 3 Interventional

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

NCT05104229
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Venous Thromboembolism
Interventions
Aspirin 81Mg Ec Tab, Standard of Care
Drug
Lead sponsor
Stefan Holubar MD MS FACS, FASCRS
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Effects of Delayed Cord Clamping in Very Low Birth Weight Infants

NCT00840983
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Intraventricular Hemorrhage, Late Onset Neonatal Sepsis, Motor Skills Disorders
Interventions
delayed cord clamping
Procedure
Lead sponsor
University of Rhode Island
Other
Eligibility
Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 29, 2015 · Synced Jun 25, 2026, 5:28 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Gallotannins on the Gut Microbiome and How it Affects Inflammatory Markers Among Obese Individuals.

NCT07505212
View directory record Official record
Conditions
Obesity (Disorder)
Interventions
Gallotannin-rich mango, Lactiplantibacillus pentosus (probiotic), No Treatment Added
Dietary Supplement · Other
Lead sponsor
Prairie View A&M University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Prairie View, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

NCT01053559
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Drug
Lead sponsor
Shafran Gastroenterology Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Remission in Subjects With Crohn's Disease, 1 Year Phase

NCT00055497
View directory record Official record
Conditions
Crohn's Disease
Interventions
Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
43
States / cities
Berkeley, California • Long Beach, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2011 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 4 Interventional Results available

Triple Combination Therapy in High Risk Crohn's Disease (CD)

NCT02764762
View directory record Official record
Conditions
Crohn Disease
Interventions
Vedolizumab, Adalimumab, Methotrexate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Dothan, Alabama • Clearwater, Florida • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jun 25, 2026, 5:28 PM EDT
Completed No phase listed Observational Results available

Assessment of Colonic Epithelial Integrity With Mucosal Impedance

NCT03165058
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
mucosal impedance (MI) testing
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jun 25, 2026, 5:28 PM EDT
Withdrawn Not applicable Interventional

A Crohn's Disease Diet to Reduce Symptoms of Crohn's Disease

NCT01897090
View directory record Official record
Conditions
Crohn's Disease
Interventions
Elimination Diet, Dietary Guidelines for Americans
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

NCT03675477
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

NCT01393899
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
41
States / cities
Anaheim, California • Cypress, California • Oceanside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jun 25, 2026, 5:28 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
90
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility

NCT05332639
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Crohn Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis
Interventions
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool, Standard Crohn's Disease Education
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients

NCT00069498
View directory record Official record
Conditions
HIV Infections
Interventions
5-aminosalicylic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT03196427
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease

NCT02976129
View directory record Official record
Conditions
Crohn's Disease
Interventions
V565, Placebo
Drug
Lead sponsor
VHsquared Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Anaheim, California • Clearwater, Florida • Miami Springs, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jun 25, 2026, 5:28 PM EDT